ELA026 Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Pipeline

Phase 1: 1

Top Sponsors

Electra Therapeutics Inc.1

Indications

T-cell Malignancies1
Cancer1

New Haven, Connecticut1 trial

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Yale New Haven Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.